Recombinant Human PSG9 (C-6His)

Description

EnkiLife provides the Recombinant Human PSG9 (C-6His) protein,aslo know as Pregnancy-specific beta-1-glycoprotein 9,PS-beta-G-9,PSBG-9,Pregnancy-specific glycoprotein 9,PS34,Pregnancy-specific beta-1 glycoprotein B,PS-beta-B,Pregnancy-specific beta-1-glycoprotein 11,PS-beta-G-11,PSBG-11,Pregnancy-specific glycoprotein 11,Pregnancy-specific glycoprotein 7,PSG7,PSG11, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human Pregnancy-specific Beta-1-glycoprotein 9 is produced by our Mammalian expression system and the target gene encoding Glu35-Ser426 is expressed with a 6His tag at the C-terminus.Accession:AAH20759.1. Expression Host:Human Cells.Species:Human.Predicted Molecular Mass:45.6 KDa. Background:Pregnancy-specific beta-1-glycoprotein 9(PSG9) is a secreted protein and contains 3 Ig-like C2-type (immunoglobulin-like) domains, 1 Ig-like V-type (immunoglobulin-like) domain. It is a member of the PSG family, a group of closely related secreted glycoproteins that are highly expressed in fetal placental syncytiotrophoblast cells. The members of the PSG protein family all have a characteristic N-terminal domain that is homologous to the immunoglobulin variable region. PSGs become detectable in serum during the first two to three weeks of pregnancy and increase as the pregnancy progresses, eventually representing the most abundant fetal protein in the maternal blood at term. PSGs function to stimulate secretion of TH2-type cytokines from monocytes, and they may also modulate the maternal immune system during pregnancy, thereby protecting the semi-allotypic fetus from rejection. PSGs are commonly expressed in trophoblast tumors. Eleven human PSG proteins (PSG1-PSG11) have been described.